In October 2025, Oral BioLife launched Restoris™ in partnership with Phibro Animal Health Corporation. This veterinary dental gel, designed to treat periodontal bone loss in companion animals, represents our first commercial product.
Some might ask: why start with pets?
The answer lies in both strategic positioning and scientific validation.
Companion Animals Face the Same Problem
Periodontal disease is the most common clinical condition in adult dogs and cats. By age three, most pets have some form of dental disease. Left untreated, it leads to the same outcome as in humans: bone loss, loose teeth, and eventual tooth loss.
The veterinary market has the same gap as human medicine—treatments that manage disease but don't regenerate bone. Pet owners increasingly seek advanced care for their animals, creating demand for regenerative solutions.
A Faster Path to Market
Veterinary products face a different regulatory environment than human therapeutics. This allowed us to bring Restoris to market years before Ambrilux will be available for human patients.
But speed wasn't the only consideration. Launching a commercial product accomplishes several important goals:
- Revenue generation. Restoris provides near-term revenue while our human programs advance through clinical development.
- Manufacturing scale-up. Commercial production of Restoris builds our manufacturing capabilities and supply chain.
- Real-world data. Every treated animal generates data on product performance, handling characteristics, and clinical outcomes.
- Market presence. Restoris establishes Oral BioLife as a company with products in the market, not just in the lab.
The Partnership Model
Our collaboration with Phibro Animal Health gives Restoris access to an established distribution network reaching veterinary practices nationwide. Phibro brings commercial infrastructure and veterinary market expertise; we bring the novel regenerative technology.
This partnership model—leveraging others' commercial capabilities while we focus on platform development—may inform our approach to human markets as well.
What Restoris Teaches Us
Every Restoris treatment is a data point. We're learning how clinicians use the product, how patients (and their owners) respond, and how bone regenerates across diverse real-world conditions.
This learning directly informs our human development programs. The piezoelectric mechanism is the same. The scaffold chemistry is similar. The clinical questions overlap.
When Ambrilux enters human trials, we won't be starting from zero. We'll have commercial experience with a related product, manufacturing processes that have produced thousands of units, and a team that has navigated product launch.
Two Markets, One Platform
Restoris and Ambrilux are both expressions of our core piezoelectric regenerative platform. Success in veterinary medicine validates the science and builds the company. Success in human medicine transforms patient care.
We're pursuing both—because both represent enormous unmet needs, and because the platform serves both.